WO2003035074A1 - Medicaments comprenant une combinaison de derives de triazaspiro[5,5]undecane et d'un inhibiteur 3a4 d'isoenzyme p450 cytochrome et/ou d'un inhibiteur de p-glycoproteine - Google Patents

Medicaments comprenant une combinaison de derives de triazaspiro[5,5]undecane et d'un inhibiteur 3a4 d'isoenzyme p450 cytochrome et/ou d'un inhibiteur de p-glycoproteine Download PDF

Info

Publication number
WO2003035074A1
WO2003035074A1 PCT/JP2002/002552 JP0202552W WO03035074A1 WO 2003035074 A1 WO2003035074 A1 WO 2003035074A1 JP 0202552 W JP0202552 W JP 0202552W WO 03035074 A1 WO03035074 A1 WO 03035074A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
drugs
combination
triazaspiro
isozyme
Prior art date
Application number
PCT/JP2002/002552
Other languages
English (en)
French (fr)
Inventor
Haruo Imawaka
Shiro Shibayama
Yoshikazu Takaoka
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Priority to JP2003537641A priority Critical patent/JPWO2003035074A1/ja
Priority to BR0213372-5A priority patent/BR0213372A/pt
Priority to IL16105302A priority patent/IL161053A0/xx
Priority to CA002461545A priority patent/CA2461545A1/en
Priority to KR10-2004-7005835A priority patent/KR20040045882A/ko
Priority to HU0500028A priority patent/HUP0500028A2/hu
Priority to MXPA04003816A priority patent/MXPA04003816A/es
Priority to EP02705299A priority patent/EP1438962A4/en
Publication of WO2003035074A1 publication Critical patent/WO2003035074A1/ja
Priority to NO20041618A priority patent/NO20041618L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
PCT/JP2002/002552 2001-10-23 2002-03-18 Medicaments comprenant une combinaison de derives de triazaspiro[5,5]undecane et d'un inhibiteur 3a4 d'isoenzyme p450 cytochrome et/ou d'un inhibiteur de p-glycoproteine WO2003035074A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2003537641A JPWO2003035074A1 (ja) 2001-10-23 2002-03-18 トリアザスピロ［５．５］ウンデカン誘導体とチトクロムｐ４５０アイソザイム３ａ４阻害剤および／またはｐ糖タンパク質阻害剤との組み合わせからなる医薬
BR0213372-5A BR0213372A (pt) 2001-10-23 2002-03-18 Medicamento compreendendo combinação de derivado de traizaespiro[5,5]undecano com inibidor de citocromo p450 isozima 3a4 e/ou inibidor de glocoproteìna-p
IL16105302A IL161053A0 (en) 2001-10-23 2002-03-18 Drugs comprising combination of triazaspiro [5,5] undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or p-glycoprotein inhibitor
CA002461545A CA2461545A1 (en) 2001-10-23 2002-03-18 Drugs comprising combination of triazaspiro¬5,5|undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or p-glycoprotein inhibitor
KR10-2004-7005835A KR20040045882A (ko) 2001-10-23 2002-03-18 트리아자스피로[5.5]운데칸 유도체와 시토크롬 ｐ450이소자임 3ａ4 억제제 및/또는 ｐ-당단백질 억제제를조합한 의약
HU0500028A HUP0500028A2 (hu) 2001-10-23 2002-03-18 Triaza-spiro[5.5]undekán-azármazék citokróm P450 izozim 3A4 inhibitorral és/vagy P-glikoprotein inhibitorral való kombinációját tartalmazó gyógyszer
MXPA04003816A MXPA04003816A (es) 2001-10-23 2002-03-18 Medicamento que comprende combinacion de derivado de triazaespiro[5.5]undecano con inhibidor de isozima 3a4 de citocromo p450 y/o inhibidor de p-glicoproteina.
EP02705299A EP1438962A4 (en) 2001-10-23 2002-03-18 A COMBINATION OF TRIAZASPIRO-,55,5! -ANDECAN DERIVATIVE AND A CYTOCHROM P450 ISOZYM 3A4 INHIBITOR AND / OR P-GLYCOPROTEIN INHIBITOR COMPRISING MEDICAMENTS
NO20041618A NO20041618L (no) 2001-10-23 2004-04-21 Legemidler omfattende en kombinasjon av triazaspiro[5,5]undekanderivat med cytokrom P450 isozyn 3A4 inhibitor og/eller P-glykoproeininhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-324435 2001-10-23
JP2001324435 2001-10-23

Publications (1)

Publication Number Publication Date
WO2003035074A1 true WO2003035074A1 (fr) 2003-05-01

Family

ID=19141164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/002552 WO2003035074A1 (fr) 2001-10-23 2002-03-18 Medicaments comprenant une combinaison de derives de triazaspiro[5,5]undecane et d'un inhibiteur 3a4 d'isoenzyme p450 cytochrome et/ou d'un inhibiteur de p-glycoproteine

Country Status (15)

Country Link
EP (1) EP1438962A4 (ja)
JP (1) JPWO2003035074A1 (ja)
KR (1) KR20040045882A (ja)
CN (1) CN1571671A (ja)
BR (1) BR0213372A (ja)
CA (1) CA2461545A1 (ja)
CZ (1) CZ2004500A3 (ja)
HU (1) HUP0500028A2 (ja)
IL (1) IL161053A0 (ja)
MX (1) MXPA04003816A (ja)
NO (1) NO20041618L (ja)
PL (1) PL370280A1 (ja)
RU (1) RU2004115621A (ja)
WO (1) WO2003035074A1 (ja)
ZA (1) ZA200403086B (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026873A1 (ja) * 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. トリアザスピロ[５.５]ウンデカン誘導体およびそれらを有効成分とする薬剤
WO2004026874A1 (ja) * 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. トリアザスピロ[５.５]ウンデカン誘導体の新規結晶
WO2004094424A1 (ja) * 2003-04-21 2004-11-04 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003608A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
JP2008535862A (ja) 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
JPWO2006129679A1 (ja) * 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
KR100709555B1 (ko) * 2005-09-29 2007-04-20 한국과학기술연구원 고성능 액체크로마토그래피-질량분석기를 이용한 혈장 중의에이즈 치료제 검출 방법
CN101977610B (zh) 2008-01-25 2012-05-16 奇默里克斯公司 治疗病毒感染的方法
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
CN104535774B (zh) * 2015-01-16 2017-04-19 中国药科大学 一种炎性肠病状态下药物敏感性的新检测指标及其在药物治疗方案设计中的应用
KR102203334B1 (ko) 2019-04-12 2021-01-15 성균관대학교산학협력단 피모자이드의 항암제 병용요법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020980A1 (en) * 1994-02-02 1995-08-10 The Regents Of The University Of California Method for increasing bioavailability of oral pharmaceutical compositions
WO2001040227A1 (fr) * 1999-12-03 2001-06-07 Ono Pharmaceutical Co., Ltd. Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020980A1 (en) * 1994-02-02 1995-08-10 The Regents Of The University Of California Method for increasing bioavailability of oral pharmaceutical compositions
WO2001040227A1 (fr) * 1999-12-03 2001-06-07 Ono Pharmaceutical Co., Ltd. Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAEDA K. ET AL.: "Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 37, September 2001 (2001-09-01), pages 35194 - 35200, XP002952773 *
See also references of EP1438962A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026873A1 (ja) * 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. トリアザスピロ[５.５]ウンデカン誘導体およびそれらを有効成分とする薬剤
WO2004026874A1 (ja) * 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. トリアザスピロ[５.５]ウンデカン誘導体の新規結晶
US7361758B2 (en) 2002-09-18 2008-04-22 Ono Pharmaceutical Co., Ltd. Crystals of triazaspiro[5.5]undecane derivative
WO2004094424A1 (ja) * 2003-04-21 2004-11-04 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその用途

Also Published As

Publication number Publication date
NO20041618L (no) 2004-07-22
RU2004115621A (ru) 2005-03-27
CN1571671A (zh) 2005-01-26
EP1438962A4 (en) 2005-11-09
JPWO2003035074A1 (ja) 2005-02-10
MXPA04003816A (es) 2004-07-30
HUP0500028A2 (hu) 2005-04-28
CA2461545A1 (en) 2003-05-01
ZA200403086B (en) 2005-05-11
KR20040045882A (ko) 2004-06-02
CZ2004500A3 (cs) 2005-03-16
IL161053A0 (en) 2004-08-31
EP1438962A1 (en) 2004-07-21
BR0213372A (pt) 2005-02-01
PL370280A1 (en) 2005-05-16

Similar Documents

Publication Publication Date Title
WO2003035074A1 (fr) Medicaments comprenant une combinaison de derives de triazaspiro[5,5]undecane et d'un inhibiteur 3a4 d'isoenzyme p450 cytochrome et/ou d'un inhibiteur de p-glycoproteine
WO2003040096A3 (en) N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
AU2719300A (en) Antimicrobial compositions containing photosensitizers, articles, and methods ofuse
AU2003233010A1 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
EP1378509A4 (en) DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE
IL166527A0 (en) Macrolide compounds endowed with antiinflammatory activity
AU2001291893A1 (en) Use of substituted imidazo(1,2-a)pyridine-, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine-3-yl-amine derivatives for producing NOS-inhibiting medicaments
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
AU2002356256A1 (en) 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo-(3.2.2)nonane derivatives, preparation and therapeutic use thereof
WO2002026697A3 (en) Aromatic derivatives with hiv integrase inhibitory properties
WO2001047928A3 (de) Imidazo 1,3,5 triazinone und ihre verwendung
AU2002238947A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
WO2004063330A3 (en) (2-carboxamido) (3-amino) thiophene compounds
WO2002094020A8 (de) Verwendung von triazolopyrimidin-derivaten als mikrobizide im materialschutz
CA2400704A1 (en) 8,8a-dihydro-indeno[1,2-d]thiazole derivatives with a sulphonamido or sulphono substituent in the 2 position, a method for production thereof and use thereof as a medicament
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
CA2138289A1 (en) N-substituted azabicycloheptane derivatives, the preparation and use thereof
WO2003008365A3 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
WO2000026399A3 (de) Verfahren zur herstellung von quercetin- und isoquercetin-derivaten
WO2001009122A3 (en) Serotonergic benzofurans
WO2004062562A3 (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
AU6831500A (en) 1h-pirido[3, 4-b]indol-1-one derivatives
AU2003252467A1 (en) Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
WO1997013776A3 (fr) Nouveaux derives amines de 2', 3' didesoxyglycosides d'epipodophyllotoxine, leur procede de preparation, leur utilisation comme medicament et leur utilisation destinee aux traitements anticancereux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003537641

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002705299

Country of ref document: EP

Ref document number: 2461545

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 161053

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2004-500

Country of ref document: CZ

Ref document number: 20028203917

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 532413

Country of ref document: NZ

Ref document number: 2002238945

Country of ref document: AU

Ref document number: 1020047005835

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004/03086

Country of ref document: ZA

Ref document number: 200403086

Country of ref document: ZA

Ref document number: PA/A/2004/003816

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2002705299

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2004-500

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2004-500

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2002705299

Country of ref document: EP